已收盘 12-19 16:00:00 美东时间
+1.045
+9.22%
YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest
12-16 22:05
YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has reached a
11-25 04:19
YD Bio Limited ("YD Bio" or the "Company") (NASDAQGM:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global
11-05 21:35
YD Bio Limited rang the Nasdaq Opening Bell to celebrate its public listing, marking a milestone in its journey as a biotechnology company. The listing strengthens its capital base, enhances its global visibility, and accelerates the commercialization of its innovative diagnostic and regenerative medicine platforms. YD Bio, founded in 2013, has evolved from a clinical trial drug supplier to a diversified biotech innovator, leveraging strategic pa...
10-20 14:20
YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG
10-10 20:39
YD Bio's partner, EG Biomed, has achieved CAP accreditation for its CLIA-certified laboratory, enhancing its ability to deliver advanced diagnostic tests in the U.S. This milestone strengthens YD Bio's commitment to innovation in cancer detection and ophthalmology. EG Biomed's Chief R&D Officer also presented new findings on a novel biomarker for pancreatic cancer at the AACR conference.
10-10 12:37
YD Bio Limited announced its unaudited financial results for the six months ended June 30, 2025. The company secured $13.2 million to support YD Biopharma's operations following its merger with Breeze Holdings. Despite a 9% net revenue decline to $204,007, YD Biopharma continued investing in R&D and advanced two licensed patents to expand capacity. The top five products accounted for 56% of total revenue, with Keytruda injection being the top ear...
09-30 21:25
股价周内狂飙近300%!uniQure在研创新药获重大进展;特朗普政府"盯上"锂矿巨头股权,Lithium Americas周内大涨95%>>
09-28 10:10
U.S. stocks were lower, with the Dow Jones index falling more than 150 points o...
09-25 02:18
核电股Oklo周涨超63%,有消息称特朗普政府正全力推进大型电力项目建设;RGTI周涨近50%,与美国空军研究实验室合作推进超导昆腾网络技术>>
09-20 10:40